Thyroid carcinoma, while often detected early and treated effectively, can evolve into aggressive forms that resist conventional therapies. Advanced stages characterized by progression despite radioactive iodine therapy and other systemic treatments present a significant clinical challenge. The GETNE-DUTHY trial addresses this unmet need by investigating the dual blockade of immune checkpoints, a strategy designed to unleash the body’s immune system against tumor cells that have otherwise developed mechanisms to evade immune detection.

Durvalumab is a human monoclonal antibody targeting PD-L1, a ligand engaged by tumor cells to inhibit T-cell function, thereby promoting immune escape. Tremelimumab, similarly, is a monoclonal antibody directed against CTLA-4, an inhibitory receptor expressed on T cells that downregulates immune responses. By concurrently inhibiting these two immune checkpoints, their combined administration aims to potentiate antitumor immunity more effectively than single-agent therapies, reinvigorating T-cell activity within the tumor microenvironment.

The GETNE-DUTHY trial enrolled patients presenting with progressive, refractory advanced thyroid carcinoma, a cohort defined by measurable disease that continued to worsen despite standard-of-care treatments. This clinical investigation was meticulously designed to evaluate the efficacy and safety profile of the durvalumab-tremelimumab combination. The trial employed rigorous inclusion criteria, robust imaging assessments for response evaluation, and comprehensive biomarker analyses to dissect the immunological dynamics induced by therapy.

Preliminary outcomes from this study illuminate a promising therapeutic trajectory. Participants demonstrated clinically meaningful responses, including partial and complete tumor regressions, extending progression-free survival compared to historically documented outcomes in similar patient populations. Notably, the durability of responses observed suggests that this immune checkpoint blockade duo may induce long-lasting immunological memory, a critical component in the management of refractory malignancies.

Despite its promise, the use of combined immune checkpoint inhibitors necessitates careful consideration of the safety landscape. Immune-related adverse events (irAEs), often manifesting as inflammation in organs such as the skin, liver, lungs, and endocrine glands, were monitored meticulously. Data revealed an acceptable safety profile consonant with prior experiences in other solid tumors, with adverse events manageable through established clinical algorithms involving corticosteroids and immunosuppressants when needed.

The mechanistic insights provided by translational studies embedded within the trial are equally illuminating. Tumor biopsies pre- and post-treatment indicated enhanced infiltration of cytotoxic CD8+ T cells and reduction of regulatory T cells within the tumor milieu, corroborating the restoration of immune competence. Additionally, shifts in cytokine profiles pointed towards a reinvigoration of pro-inflammatory pathways critical for sustained antitumor effects.

Moreover, exploratory analyses suggested potential biomarkers predictive of response, notably the expression levels of PD-L1 and the tumor mutational burden (TMB), which may guide patient selection in future clinical applications. The identification of such biomarkers is pivotal in refining therapeutic approaches, minimizing unnecessary exposure to adverse effects, and enhancing cost-effectiveness in oncology care.

One transformative aspect of the GETNE-DUTHY trial is its contribution to the evolving paradigm of immunotherapy in thyroid cancers, a field where immune checkpoint blockade has classically demonstrated more modest results compared to malignancies like melanoma or non-small cell lung cancer. By evidencing that combination strategies can overcome intrinsic tumor resistance, this study paves the way for future trials integrating immunotherapy with other modalities such as targeted therapies or novel immune modulators.

The trial’s implications extend beyond clinical endpoints. The design, incorporating real-time immune monitoring and patient-reported outcome measures, epitomizes the integration of precision medicine principles into oncological research. This approach not only facilitates a deeper understanding of therapeutic responses but also ensures that the patient’s quality of life remains a central consideration in treatment advances.

As the oncology community digests the findings of the GETNE-DUTHY trial, questions regarding the optimal dosing schedules, treatment duration, and management of irAEs will undoubtedly prompt further investigative efforts. Additionally, the potential synergistic effects of combining immune checkpoint inhibitors with external beam radiation or other immune-stimulating strategies warrant exploration to maximize therapeutic efficacy in this challenging patient subset.

In conclusion, the GETNE-DUTHY phase II trial marks a significant milestone in the quest for effective therapies against progressive, refractory advanced thyroid carcinoma. The synergy between durvalumab and tremelimumab not only reinvigorates T-cell immunity but also redefines the therapeutic possibilities for patients who previously confronted limited options. While challenges remain, the horizon of thyroid cancer treatment has expanded, heralding a new chapter where immunotherapy holds the promise to transform patient outcomes fundamentally.

Subject of Research: Progressive, refractory advanced thyroid carcinoma treatment with immune checkpoint inhibitors.

Article Title: Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Article References:

Capdevila, J., Hernando, J., Molina-Cerillo, J. et al. Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71155-y

Image Credits: AI Generated

Glioblastoma remains the most aggressive primary brain malignancy found in adults, presenting clinicians with formidable therapeutic challenges. The prognosis is bleak, frequently culminating in median survivals barely exceeding a year despite maximal surgical debulking followed by concurrent radiation and TMZ chemotherapy. This grim outlook is further compounded in tumors exhibiting unmethylated O6-methylguanine-DNA methyltransferase (uMGMT) promoters, which are notably resistant to TMZ’s alkylating effects. Approximately 60% of glioblastoma cases fall under this uMGMT classification, underscoring a critical unmet need for more effective systemic therapies that transcend current chemotherapy limitations.

The rationale behind NRG-BN007 stemmed from intriguing phase I safety data garnered in the predecessor trial NRG-BN002, which revealed that combining ipilimumab and nivolumab with radiotherapy was tolerable for patients with newly diagnosed glioblastoma. Given the revolutionary success of these immunotherapies in other malignancies—particularly metastatic melanoma and non-small cell lung cancer—investigators posited that unleashing the immune system via dual checkpoint blockade might overcome the immune-suppressive microenvironment characteristic of glioblastoma. This trial was therefore meticulously designed to evaluate whether such immunotherapy in combination with radiation could not only halt disease progression but eventually enhance overall survival.

NRG-BN007 enrolled 159 eligible participants, who were stratified by recursive partitioning analysis class and planned use of Tumor Treating Fields, a device delivering alternating electric fields purported to disrupt tumor cell division. Patients were randomized to receive either the experimental combination of ipilimumab and nivolumab or the conventional approach of radiation plus temozolomide. Importantly, the study was powered to detect a hazard ratio for PFS of 0.58 or less—a statistically significant threshold that would warrant progression to a phase III evaluation of overall survival impact.

After 100 centrally adjudicated progression events, a critical preplanned interim analysis was performed. The data revealed median progression-free survival to be 7.7 months in the immunotherapy arm compared to 8.5 months in the temozolomide arm. The hazard ratio favored the control arm at 1.47 (70% confidence interval 1.19–1.83), and the one-sided p-value was 0.96, indicating no meaningful difference. Survival data remain immature with over half the cohort still alive, but initial median overall survival figures hovered around 13 months for both groups, with no statistically significant divergence detected.

These findings have immediate clinical implications. The failure to demonstrate superior PFS in phase II effectively precludes the transition to a larger phase III study focused on overall survival, thereby curtailing further assessment of this immunotherapy combination in uMGMT glioblastoma. It marks a sobering reminder of the intrinsic challenges in modifying the glioblastoma tumor microenvironment, which is characterized by robust immunosuppressive features and the blood-brain barrier’s protective effects.

Despite these setbacks, researchers remain undeterred, emphasizing the vital importance of ongoing biomarker analyses currently underway. These in-depth investigations aim to discern whether specific molecular or immunologic subsets of patients may still derive benefit from checkpoint blockade, facilitating a more personalized approach to immunotherapy in glioblastoma. Subgroup analyses and exploratory endpoints leveraging genomic, transcriptomic, and immune profiling data will be pivotal in refining future therapeutic strategies.

Andrew B. Lassman, MD, MSc, the lead author of the NRG-BN007 manuscript and a prominent neuro-oncologist at Columbia University’s Vagelos College of Physicians & Surgeons, underscored the commitment within the field to persistently explore innovative avenues to improve outcomes in MGMT-unmethylated glioblastoma. He highlighted the significance of the trial’s results in guiding clinical decision-making and redirecting resources towards potentially more fruitful therapeutic avenues.

The NRG Oncology cooperative group orchestrating this study integrates expertise from a broad spectrum of disciplines, including radiation oncology, medical oncology, neurosurgery, pathology, and biostatistics. Established in 2012, this extensive clinical trials network leverages more than 1,300 research sites globally, primarily within the United States and Canada, to conduct rigorously designed, multi-institutional studies aimed at advancing cancer care. NRG Oncology continues to be financially underpinned primarily by the National Cancer Institute and collaborates closely with pharmaceutical partners such as Bristol Myers Squibb, which provided support under a Cooperative Research and Development Agreement.

Looking forward, the glioblastoma landscape demands parallel investigations into novel therapeutic modalities, including but not limited to tumor-targeted viral therapies, metabolic interventions, and adaptive immunotherapies such as CAR-T cells or neoantigen vaccines. These approaches face technical obstacles but hold promise to unsettle the tumor’s immunosuppressive fortress. Furthermore, enhancing drug delivery across the blood-brain barrier remains a critical focus to maximize treatment efficacy.

In sum, the NRG-BN007 trial serves as a potent scientific and clinical inflection point, elucidating that dual immune checkpoint blockade with ipilimumab and nivolumab, in combination with radiation, does not enhance progression-free survival compared to standard temozolomide and radiation in newly diagnosed uMGMT glioblastoma patients. While this closes one door, it galvanizes the field to refine biomarker-driven patient selection and pursue alternative immunotherapeutic strategies to improve the dismal prognosis of this unforgiving disease.

Subject of Research: The efficacy of dual immune checkpoint inhibitor therapy combined with radiation versus temozolomide and radiation in newly diagnosed MGMT-unmethylated glioblastoma.

Article Title: Dual Immune Checkpoint Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.

News Publication Date: August 8, 2025.

Web References:

• Clinical Trial Registry: https://clinicaltrials.gov/study/NCT04396860
• Published Article DOI: https://doi.org/10.1200/JCO-25-00618

References:
Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, et al. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Aug 8:JCO2500618. doi: 10.1200/JCO-25-00618. Epub ahead of print. PMID: 40779733.

Keywords: Glioblastomas, Brain Cancer, MGMT-Unmethylated, Immunotherapy, Ipilimumab, Nivolumab, Radiation Therapy, Temozolomide, Progression-Free Survival, Neuro-Oncology, Clinical Trial, NRG Oncology